Browsing by Author "Chang, Rui"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Immunoreactivity of Pluripotent Markers SSEA-5 and L1CAM in Human Tumors, Teratomas, and Induced Pluripotent Stem Cells
    (Hindawi Publishing Corporation, 2013) Cassidy, Linda; Choi, Meerim; Meyer, Jason; Chang, Rui; Seigel, Gail M.; Department of Biology, School of Science
    Pluripotent stem cell markers can be useful for diagnostic evaluation of human tumors. The novel pluripotent marker stage-specific embryonic antigen-5 (SSEA-5) is expressed in undifferentiated human induced pluripotent cells (iPSCs), but little is known about SSEA-5 expression in other primitive tissues (e.g., human tumors). We evaluated SSEA-5 immunoreactivity patterns in human tumors, cell lines, teratomas, and iPS cells together with another pluripotent cell surface marker L1 cell adhesion molecule (L1CAM). We tested two hypotheses: (1) SSEA-5 and L1CAM would be immunoreactive and colocalized in human tumors; (2) SSEA-5 and L1CAM immunoreactivity would persist in iPSCs following retinal differentiating treatment. SSEA-5 immunofluorescence was most pronounced in primitive tumors, such as embryonal carcinoma. In tumor cell lines, SSEA-5 was highly immunoreactive in Capan-1 cells, while L1CAM was highly immunoreactive in U87MG cells. SSEA-5 and L1CAM showed colocalization in undifferentiated iPSCs, with immunopositive iPSCs remaining after 20 days of retinal differentiating treatment. This is the first demonstration of SSEA-5 immunoreactivity in human tumors and the first indication of SSEA-5 and L1CAM colocalization. SSEA-5 and L1CAM warrant further investigation as potentially useful tumor markers for histological evaluation or as markers to monitor the presence of undifferentiated cells in iPSC populations prior to therapeutic use.
  • Thumbnail Image
    Item
    Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease
    (Wiley, 2023) Chang, Rui; Trushina, Eugenia; Zhu, Kuixi; Zaidi, Syed Shujaat Ali; Lau, Branden M.; Kueider-Paisley, Alexandra; Moein, Sara; He, Qianying; Alamprese, Melissa L.; Vagnerova, Barbora; Tang, Andrew; Vijayan, Ramachandran; Liu, Yanyun; Saykin, Andrew J.; Brinton, Roberta D.; Kaddurah-Daouk, Rima; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Metabolomics Consortium; Radiology and Imaging Sciences, School of Medicine
    Introduction: Late-onset Alzheimer's disease (LOAD) is a complex neurodegenerative disease characterized by multiple progressive stages, glucose metabolic dysregulation, Alzheimer's disease (AD) pathology, and inexorable cognitive decline. Discovery of metabolic profiles unique to sex, apolipoprotein E (APOE) genotype, and stage of disease progression could provide critical insights for personalized LOAD medicine. Methods: Sex- and APOE-specific metabolic networks were constructed based on changes in 127 metabolites of 656 serum samples from the Alzheimer's Disease Neuroimaging Initiative cohort. Results: Application of an advanced analytical platform identified metabolic drivers and signatures clustered with sex and/or APOE ɛ4, establishing patient-specific biomarkers predictive of disease state that significantly associated with cognitive function. Presence of the APOE ɛ4 shifts metabolic signatures to a phosphatidylcholine-focused profile overriding sex-specific differences in serum metabolites of AD patients. Discussion: These findings provide an initial but critical step in developing a diagnostic platform for personalized medicine by integrating metabolomic profiling and cognitive assessments to identify targeted precision therapeutics for AD patient subgroups through computational network modeling.
  • Thumbnail Image
    Item
    Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
    (Springer Nature, 2020) Arnold, Matthias; Nho, Kwangsik; Kueider-Paisley, Alexandra; Massaro, Tyler; Huynh, Kevin; Brauner, Barbara; MahmoudianDehkordi, Siamak; Louie, Gregory; Moseley, M. Arthur; Thompson, J. Will; St. John-Williams, Lisa; Tenenbaum, Jessica D.; Blach, Colette; Chang, Rui; Brinton, Roberta D.; Baillie, Rebecca; Han, Xianlin; Trojanowski, John Q.; Shaw, Leslie M.; Martins, Ralph; Weiner, Michael W.; Trushina, Trushina; Toledo, Jon B.; Meikle, Peter J.; Bennett, David A.; Krumsiek, Jan; Doraiswamy, P. Murali; Saykin, Andrew J.; Kaddurah-Daouk, Rima; Kastenmüller, Gabi; Radiology and Imaging Sciences, School of Medicine
    Late-onset Alzheimer’s disease (AD) can, in part, be considered a metabolic disease. Besides age, female sex and APOE ε4 genotype represent strong risk factors for AD that also give rise to large metabolic differences. We systematically investigated group-specific metabolic alterations by conducting stratified association analyses of 139 serum metabolites in 1,517 individuals from the AD Neuroimaging Initiative with AD biomarkers. We observed substantial sex differences in effects of 15 metabolites with partially overlapping differences for APOE ε4 status groups. Several group-specific metabolic alterations were not observed in unstratified analyses using sex and APOE ε4 as covariates. Combined stratification revealed further subgroup-specific metabolic effects limited to APOE ε4+ females. The observed metabolic alterations suggest that females experience greater impairment of mitochondrial energy production than males. Dissecting metabolic heterogeneity in AD pathogenesis can therefore enable grading the biomedical relevance for specific pathways within specific subgroups, guiding the way to personalized medicine.